Abstract: The patent application pertains to compositions and methods for reducing Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) expression and for reducing serum cholesterol in mammalian subjects. The exemplary compositions comprise heat0 shock protein HSP27 or fragments thereof and/or a HSP25, or fragments thereof in a mixture with an adjuvant. The compositions may optionally comprise anti-HSP27 antibody. The method for reducing serum cholesterol relate to the use of the compositions to increase the subject's levels of serum HSP27 and/or anti-HSP27 antibodies.

Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Abstract: CD20 antibodies with improved characteristics. Some embodiments describe antibodies comprising a mouse IgG2; a human IgG1, IgA1 or IgA2 constant region and a variable domain that can bind the epitope “EPANpSEK” (SEQ ID NO:31) on human CD20 expressed on Ramos cells and which antibody has an increased PCD functionality when compared to Rituximab with a constant region of the same isotype.

Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.

Abstract: The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.

Abstract: The application discloses an anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibody, an amino acid sequence comprising coded antibody variable regions and Complementarity-Determining Regions (CDR), the obtaining method, and application of monoclonal antibody. The anti-PCSK9 monoclonal antibodies are screened from a phage antibody library; affinity maturation is achieved by using a method that the phage antibody library is established by means of chain displacement; After screening the light chain CDR1, 2, 3 Mutant Library of monoclonal antibodies obtained from primary screening; monoclonal antibodies having high affinity are selected; then screening the mutant libraries of heavy chain CDR1, 2, 3 regions; and finally the monoclonal antibodies having high affinity are screened.

Abstract: Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.

Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

Abstract: Certain embodiments provide isolated anti-MMP-14 antibodies or fragments thereof, isolated anti-MMP-12 antibodies or fragments thereof, isolated anti-BACE-1 antibodies or fragments thereof, isolated anti-Alp2 antibodies or fragments thereof, and isolated anti-cathepsin B antibodies or fragments thereof, as well as methods of use thereof.

Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.

Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.

Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Abstract: Anti-HLA-C6 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as autoimmune diseases.

Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.

Abstract: The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also relates to compositions comprising said variant IgG4 antibodies.

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.

Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.

Abstract: In an aspect, the invention relates to compositions, method, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.